sC5b-9 Antibody (Monoclonal - neoantigen)

A murine monoclonal antibody to a neoantigen on the terminal complement complex.


Product Specifications

Citations 27
Clonality

Monoclonal

Immunogen Purified human protein.
Applications See citations and technical data sheet for application info.
Concentration 1.0-1.2 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human, Baboon, Cynomologus macaque, Rhesus macaque.

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A239
Catalog Number (CE) N/A
Size 100 µl
Price (USD) $365.00
Price (EURO) 330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to a neoantigen on the terminal complement complex.

Size 100 µl
Concentration

1.0-1.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Unconjugated
Cross Reactivity Human, Baboon, Cynomologus macaque, Rhesus macaque.
Isotype IgG2bk
Purity ≥ 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC.

Citations

Title Year Applications Sample Species Sample Sample Details

Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement components

2013

IF

Bacteria

Borrelia valaisiana

CspA from Borrelia burgdorferi inhibits the terminal complement pathway.

2013

IF

Bacteria

Borrelia burgdorferi

EGFR modulates complement activation in head and neck squamous cell carcinoma.

2020

IF

Cell Culture

HNSCC Cells

The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complement

2016

IF, WB

Cell Culture

Plasmodium falciparum culture

Inflammasome-Dependent Peroxiredoxin 2 Secretion Induces the Classical Complement Pathway Activation.

2021

Complement Activation Assay, WB

Human

Serum

A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein.

2018

ELISA

Human

Serum

Establishing a Case for Anti-complement Therapy in Membranous Nephropathy.

2020

ELISA

Human

Urine

Membranous Nephropathy

The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare.

2021

ELISA

Human

Plasma

Lupus Nephritis

Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients.

2021

ELISA

Human

Plasma

Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.

2022

ELISA

Human

Plasma

Antibody Mediated Rejection

CipA mediates complement resistance of Acinetobacter baumannii by formation of a factor I-dependent quadripartite assemblage.

2022

ELISA

Human

Serum

CipA

Complement Activation on Platelets Correlates with a Decrease in Circulating Immature Platelets in Patients with Immune Thrombocytopenic Purpura

2009

ELISA

Human

Plasma

Inhibition of Immune Complex Complement Activation and Neutrophil Extracellular Trap Formation by Peptide Inhibitor of Complement C1.

2018

ELISA

Human

Serum

Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide.

1998

ELISA

Human

Amyloid-βeta peptides & NHS

High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation.

2018

ELISA, IF

Human

Serum

HMGB1-coated microplates

The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro

2008

IF

Human

Placenta Tissue

The Local Complement Activation on Vascular Bed of Patients with Systemic Sclerosis: A Hypothesis-Generating Study

2015

IF

Human

Skin Tissue

The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complement

2016

IF, WB

Human

Red Blood Cells

Plasmodium falciparum incubated

Terminal complement complex formation is associated with intervertebral disc degeneration.

2020

IHC

Human

Spinal Cord Tissue

Interleukin-1β and cathepsin D modulate formation of the terminal complement complex in cultured human disc tissue.

2021

IHC

Human

Disc Tissue

Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study.

2021

IHC

Human

Placenta Tissue

Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy

2015

IHC

Human

Kidney Tissue

Thrombotic Microangiopathy

Killing of dsrA mutants of Haemophilus ducreyi by normal human serum occurs via the classical complement pathway and is initiated by immunoglobulin M binding

2005

Radiation Immunoassay

Human

Serum

Haemophilus ducreyi incubated

Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade

2006

WB

Human

Serum

Moraxella catarrhalis

Genetic engineering strategies to prevent the effects of antibody and complement on xenogeneic chondrocytes

2015

FC

Porcine

Articular chondrocytes

Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury.

2008

FC, IF

Rat

Spinal Cord Tissue

Activation of early components of complement targets myelin and oligodendrocytes in the aged rhesus monkey brain.

2005

IHC

Rhesus Monkey

Brain Tissue